Supreme Court Temporarily Restores Mail Access to Abortion Pill in the U.S.

On Monday, the United States Supreme Court reinstated broad access to the abortion pill mifepristone, temporarily suspending a Fifth Circuit Court of Appeals order that had halted its distribution via mail and telemedicine across the country.

The order, signed by Justice Samuel Alito, allows women seeking to terminate a pregnancy to obtain the pill from pharmacies or through mail delivery without needing an in-person visit to a doctor, reversing restrictions imposed just days earlier.

This measure will remain effective for at least an additional week as both parties present their arguments, giving the court time to consider the issue more comprehensively.

Background of the Legal Battle

The case originated from a lawsuit filed by the state of Louisiana against the Food and Drug Administration (FDA) in October 2025, under the case "State of Louisiana vs. the FDA."

Last Thursday, the Fifth Circuit blocked the mail shipment of the abortion pill with a unanimous order penned by Judge Stuart Kyle Duncan—appointed by former President Donald Trump—and supported by Judges Southwick and Engelhardt.

This decision overturned the FDA's policy adopted in January 2023, which had allowed telemedicine and postal delivery of mifepristone nationwide and extended its use up to ten weeks of gestation.

Arguments and Impact

Louisiana argued that the FDA's policy was based on flawed data, facilitated illegal abortions, and led to additional costs for the state's Medicaid program.

In his ruling, Judge Duncan argued that the gradual easing of safeguards around mifepristone "likely lacked basis in data and scientific literature," and that "each abortion facilitated by FDA action nullifies Louisiana's ban on medical abortions."

Mifepristone manufacturers, Danco Laboratories and GenBioPro, filed emergency appeals to the Supreme Court, resulting in the order signed on Monday.

Significance of the Decision

The decision is highly significant as medication abortions represent the majority of procedures in the United States: in 2023, 63% of all recorded abortions—approximately 642,700 cases—were medication-induced, according to the Guttmacher Institute.

In 2024, one in four abortions (25%) was conducted via telemedicine, averaging 12,330 procedures monthly by the end of the year.

The availability of mifepristone has cushioned the impact of state bans that most Republican-led states began enforcing after the 2022 Dobbs ruling, which overturned Roe v. Wade and returned abortion regulation to states.

In June 2024, the Supreme Court had unanimously dismissed a previous lawsuit against the FDA related to mifepristone—filed by the Alliance for Hippocratic Medicine—due to a lack of standing, temporarily preserving access without resolving the core issue.

Reactions and Future Outlook

Several Democratic states have enacted protective laws to shield telemedicine providers prescribing the pill to patients in states with bans, protecting them from extradition and legal actions.

Julia Kaye, an attorney with the American Civil Liberties Union (ACLU), warned that the Fifth Circuit's restriction "will impact patients' access to both abortion and miscarriage care nationwide" and added that "when telemedicine is restricted, rural communities, low-income individuals, people with disabilities, and communities of color are most affected."

Planned Parenthood described the Fifth Circuit's decision as "the greatest impact on abortion policy since Dobbs," while noting that mifepristone, approved by the FDA in 2000, has been used by roughly seven million patients in the United States since then.

The Supreme Court is expected to address the core issue once both sides present their arguments within the one-week timeframe set by Alito's order.